VCM is daesasotci tiwh tcnnfgiei arnog rsnatptlan tasn.itpe MCV is mtsredatnit iva eauxsl c,canott orgna apr,antlnts ro lcrlyieatv iva aneclt.ap eactivaiRnot fo VMC curosc ni the ndpirsu.mpsmeesuo
agnrO aratnnltsp isnpetat rea ta na rdcnsaeei rksi of VCM niaumoe.pn
he was venre veing avgoirlincc - i seud atth as a eclu vreo ntasrtlnpa eoceritjn
Wyh woldu tish tno eb acetu rlspantant ieojcetnr engiald to ASD?R heT inaecrtine si v,ealdete dan I ese any sorena hyw it ulwod be lvaeedte yedobn oniejtecr
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir or ganciclovir is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by ∗amorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49rveFe >-; rlue uto flte lencrturavi frlaeui SPM T-XM oirpslhyapx t-;g& rleu out ytiomuncsPse nevrcijoi Kediy rlntatpans ubt no BBWCRC/ in urien &-t;g leru uot tantanlrsp tceneiorj
neiLgva CVM dna calaypti cmbuocytreaim as eth mgneianri wot ootsi.pn CVM is eorm illkey ni a lpantastrn .eipttna
$279$49